Othera is a pharmaceutical company developing novel therapeutics for age-related diseases of the eye. Othera's lead compound, OT-551 is an eye drop in a Phase II clinical trial for the dry form of macular degeneration (AMD), and recently announced positive interim data from that trial, with full trial results due in mid-2010. The company is also developing novel treatments for glaucoma and neurodegenerative diseases.